Pfizer Net Income 2010-2022 | PFE

Pfizer annual/quarterly net income history and growth rate from 2010 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • Pfizer net income for the quarter ending March 31, 2022 was $7.864B, a 61.25% increase year-over-year.
  • Pfizer net income for the twelve months ending March 31, 2022 was $24.966B, a 133.74% increase year-over-year.
  • Pfizer annual net income for 2021 was $21.979B, a 139.97% increase from 2020.
  • Pfizer annual net income for 2020 was $9.159B, a 42.85% decline from 2019.
  • Pfizer annual net income for 2019 was $16.026B, a 43.69% increase from 2018.
Pfizer Annual Net Income
(Millions of US $)
2021 $21,979
2020 $9,159
2019 $16,026
2018 $11,153
2017 $21,308
2016 $7,215
2015 $6,960
2014 $9,135
2013 $22,003
2012 $14,570
2011 $10,009
2010 $8,257
2009 $8,635
Pfizer Quarterly Net Income
(Millions of US $)
2022-03-31 $7,864
2021-12-31 $3,393
2021-09-30 $8,146
2021-06-30 $5,563
2021-03-31 $4,877
2020-12-31 $846
2020-09-30 $1,469
2020-06-30 $3,489
2020-03-31 $3,355
2019-12-31 $-584
2019-09-30 $7,680
2019-06-30 $5,046
2019-03-31 $3,884
2018-12-31 $-394
2018-09-30 $4,114
2018-06-30 $3,872
2018-03-31 $3,561
2017-12-31 $12,274
2017-09-30 $2,840
2017-06-30 $3,073
2017-03-31 $3,121
2016-12-31 $775
2016-09-30 $1,355
2016-06-30 $2,047
2016-03-31 $3,038
2015-12-31 $-172
2015-09-30 $2,130
2015-06-30 $2,626
2015-03-31 $2,376
2014-12-31 $1,228
2014-09-30 $2,666
2014-06-30 $2,912
2014-03-31 $2,329
2013-12-31 $2,568
2013-09-30 $2,590
2013-06-30 $14,095
2013-03-31 $2,750
2012-12-31 $6,315
2012-09-30 $3,208
2012-06-30 $3,253
2012-03-31 $1,794
2011-12-31 $1,439
2011-09-30 $3,738
2011-06-30 $2,610
2011-03-31 $2,222
2010-12-31 $2,890
2010-09-30 $866
2010-06-30 $2,475
2010-03-31 $2,026
2009-12-31 $767
2009-09-30 $2,878
2009-06-30 $2,261
2009-03-31 $2,729
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $280.096B $81.288B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $465.363B 17.90
Eli Lilly (LLY) United States $277.095B 32.69
AbbVie (ABBV) United States $271.251B 11.89
Merck (MRK) United States $228.629B 12.92
Novartis AG (NVS) Switzerland $191.957B 13.82
GlaxoSmithKline (GSK) United Kingdom $110.111B 12.85
Novo Nordisk (NVO) Denmark $0.000B 31.56